AEGON ASSET MANAGEMENT UK Plc Increases Stock Holdings in Danaher Corporation $DHR

AEGON ASSET MANAGEMENT UK Plc boosted its position in Danaher Corporation (NYSE:DHR) by 5.5% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 152,837 shares of the conglomerate’s stock after purchasing an additional 7,996 shares during the period. AEGON ASSET MANAGEMENT UK Plc’s holdings in Danaher were worth $30,179,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the company. JGP Wealth Management LLC boosted its position in Danaher by 7.1% in the second quarter. JGP Wealth Management LLC now owns 4,127 shares of the conglomerate’s stock worth $815,000 after purchasing an additional 275 shares during the last quarter. Courier Capital LLC boosted its position in Danaher by 9.5% in the second quarter. Courier Capital LLC now owns 4,086 shares of the conglomerate’s stock worth $807,000 after purchasing an additional 353 shares during the last quarter. Sagespring Wealth Partners LLC boosted its position in Danaher by 22.4% in the second quarter. Sagespring Wealth Partners LLC now owns 5,553 shares of the conglomerate’s stock worth $1,097,000 after purchasing an additional 1,018 shares during the last quarter. Boston Trust Walden Corp boosted its position in Danaher by 0.3% in the second quarter. Boston Trust Walden Corp now owns 44,438 shares of the conglomerate’s stock worth $8,778,000 after purchasing an additional 146 shares during the last quarter. Finally, IFC Advisors LLC lifted its position in shares of Danaher by 1.9% during the 2nd quarter. IFC Advisors LLC now owns 7,389 shares of the conglomerate’s stock valued at $1,460,000 after buying an additional 135 shares in the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.

Danaher Stock Up 0.5%

Shares of DHR opened at $206.19 on Wednesday. The business’s 50 day moving average is $200.96 and its 200 day moving average is $197.13. The company has a market capitalization of $147.64 billion, a PE ratio of 43.87, a price-to-earnings-growth ratio of 2.92 and a beta of 0.77. Danaher Corporation has a 12-month low of $171.00 and a 12-month high of $279.41. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.64 by $0.16. The company had revenue of $5.94 billion for the quarter, compared to the consensus estimate of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The firm’s quarterly revenue was up 3.4% on a year-over-year basis. During the same quarter last year, the company earned $1.72 EPS. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Research analysts expect that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be paid a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Friday, September 26th. Danaher’s dividend payout ratio (DPR) is 27.23%.

Insider Transactions at Danaher

In other Danaher news, Director Teri List sold 2,778 shares of Danaher stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total value of $586,324.68. Following the sale, the director owned 20,751 shares of the company’s stock, valued at $4,379,706.06. The trade was a 11.81% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 11.20% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

DHR has been the topic of a number of analyst reports. Redburn Partners set a $220.00 price objective on Danaher in a research report on Wednesday, October 8th. Wells Fargo & Company lowered their price objective on Danaher from $210.00 to $205.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 23rd. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Danaher in a research report on Wednesday, October 8th. UBS Group lowered their price objective on Danaher from $240.00 to $225.00 and set a “buy” rating on the stock in a research report on Wednesday, July 23rd. Finally, Rothschild & Co Redburn reaffirmed a “neutral” rating and set a $220.00 price objective (down from $245.00) on shares of Danaher in a research report on Wednesday, October 8th. Seventeen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $244.60.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.